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cially influenced by the occurrence of motor complica-
tions.
CONCLUSIONS: Similar to earlier studies (Dodel et al.,
1995), an increase in costs was calculated depending on
HY stage and the occurrence of motor complications.
Compared to the medical costs, the non-medical services
contribute only in a small proportion to the overall direct
costs. The major cost factor is the drug treatment of Par-
kinson’s disease. The greatest proportion of these costs is
for drugs introduced in the last five years.
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OBJECTIVES: To assess the costs of multiple sclerosis (MS)
from a sample of 157 French patients followed during 2
years (1 year retrospectively, 1 year prospectively) and con-
secutively included from June 1995 to December 1996.
Costs included health-care consumption, lost earnings and
payment of short-term disability benefits by Social Security.
METHODS: At the time of inclusion, the costs of MS
were assessed by retrospective interviews covering a one-
year period (health-care costs and sick leaves) or since the
last consequence of MS on work (loss of earnings). The
retrospective data concerning both the health-care con-
sumption and sick leaves were completed with prospec-
tive data collected by means of a questionnaire during the
three-months following inclusion. Loss of earnings was
discounted at 5%. Cost estimates were crossed with med-
ical data at inclusion, and econometric analyses were per-
formed to assess explanatory variables of the health-care
costs.
RESULTS: Baseline statistics were: mean age, 42.9;
women, 66%; secondary progression, 37%; primary pro-
gression, 11%; median EDSS score, 5.25. Average one-
year retrospective health-care costs (N  157) amounted
to US$7,790.38 (/ US$9,713.88), with 75.4% going
towards hospital costs and 24.6% to ambulatory costs.
Main cost items were hospital stay in the neurological
ward (29.4% of the total cost) and physiotherapy
(15.4%). Three-month prospective healthcare costs
(N101) amounted to US$1,813 (/ US$2,056), with
56.5% spent on hospital costs. Physiotherapy and drugs
were the main ambulatory cost items, accounting for
40.0% and 24.6% respectively of the total prospective
ambulatory costs.
CONCLUSION: The econometric analysis showed that the
health-care costs were positively correlated with the num-
ber of years of schooling, the number of relapses, the EDSS
score and the Kurtzke sphincter subscore at inclusion,
negatively correlated with the Kurtzke sight subscore at
inclusion, and were not affected by the form of MS.
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MS affects approximately 85,000 people in the UK, of
which 25% to 40% will be RRMS patients. Treatment
costs fall largely on the NHS, but savings on social and
personal care will accrue if dependency is deferred. Sim-
plistic treatment algorithms based on crude prevalence
data may overestimate the number of patients and cost of
treatment.
OBJECTIVE: Present a treatment algorithm providing a
more realistic estimate of the number of RRMS patients
eligible for therapy, and thereby, an improved estimate of
budget implications of prescribing.
METHODS: Published prevalence data indicate the num-
ber of patients for whom treatment is theoretically eligi-
ble is 25 to 71 per 100,000 population (mid-point 48).
However, using published literature and feedback from
expert clinicians, we show that these numbers can be re-
duced to reflect those patients who will refuse injectable
therapy, are too young (below 18), have not relapsed in
the previous two years or are non-ambulatory.
RESULTS: We present an algorithm based on glatiramer
acetate, given the published evidence of long-term efficacy
and the significantly lower price (almost 30% cheaper
than the beta interferons in the UK). Using published data
to quantify the proportions of ineligible patients, the origi-
nal target population of 48 is reduced to 23. Depending on
the proportion of these patients that receives glatiramer ac-
etate, e.g., 20%, 40%, or 60%, the budget provision per
100,000 population would be £33,250, £59,850, or
£93,100 respectively, based on direct acquisition cost of
therapy alone versus best supportive care alone.
CONCLUSION: The algorithm provides a tool for deter-
mining a more realistic estimate of the RRMS population
eligible for treatment, and the direct costs to the NHS.
Given that NHS and Social Care budgets will increas-
ingly be managed jointly, budgetary impact is mitigated if
wider benefits such as deferred dependency and ability to
continue employment are taken into account.
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